RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Increased Bleeding Risk with Concomitant Use of Antiplatelet Therapy: Dabigatran vs Warfarin
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 10
SP 24
OP 25
DO 10.1177/155989771110015
UL http://mdc.sagepub.com/content/11/10/24.abstract
AB The RE-LY trial compared two doses of dabigatran (110 mg BID and 150 mg BID) with open label warfarin (target INR 2 to 3) in 18,113 patients with nonvalvular atrial fibrillation. This post hoc subanalyses from RE-LY, compares the efficacy and safety of dabigatran with warfarin in patients dependent upon use of concomitant antiplatelet therapy.